We found that BLM-administration significantly increased the αSMA-positive area in the esophagus, and BAY 63-2521 treatment significantly decreased the BLM induced αSMA positive area (Fig. 4i, k). The gene discussed is ACTA1; the disease is Bloom syndrome.